A recent case study has been published exploring a relapsing myeloma patient’s experience of taking curcumin as a complementary therapy […]
A new survey being funded by Myeloma UK and carried out by the National Institute for Health and Care Excellence […]
Myeloma UK has launched a new Infopack to provide relapsed and/or refractory patients and their families with the information they […]
Daratumumab (Darzalex®) has been granted an extended licence for use in combination with other myeloma drugs for the treatment of relapsed […]
Many of our supporters joined Myeloma UK in congratulating myeloma patient Jane, who recently celebrated reaching an important milestone since […]
The purpose of the Myeloma XII trial is to see if using a novel drug called ixazomib (Ninlaro®) can strengthen the effect of a second high-dose therapy and stem cell transplant (HDT-SCT).
Myeloma UK is looking to speak to patients with relapsing myeloma who have received a new combination treatment to help provide evidence in favour of the approval of the treatment in Scotland.